News | May 31, 2021
Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The company has reported total income of Rs.826.40 crores for FY 2020-21
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.
The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
The country has constantly worked with the spirit of public-private partnership
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Subscribe To Our Newsletter & Stay Updated
